BeOne Medicines AG (SHA:688235)

China · Delayed Price · Currency is CNY

307.10

+0.10 (0.03%)

At close: Jan 16, 2026

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2012 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2012 - 2020
U.S. Revenue	2.64B	1.96B	Log In	Log In	Log In	Upgrade
China Revenue	1.64B	1.41B	Log In	Log In	Log In	Upgrade
Europe Revenue	552.63M	362.63M	Log In	Log In	Log In	Upgrade
Rest of World Revenue	149.15M	78.81M	Log In	Log In	Log In	Upgrade
Revenue (Total)	4.97B	3.81B	Log In	Log In	Log In	Upgrade

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2012 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2012 - 2020
BRUKINSA Revenue	3.61B	2.64B	Log In	Log In	Log In	Upgrade
TEVIMBRA Revenue	709.11M	620.84M	Log In	Log In	Log In	Upgrade
XGEVA Revenue	298.51M	224.40M	Log In	Log In	Log In	Upgrade
BLINCYTO Revenue	100.59M	74.33M	Log In	Log In	Log In	Upgrade
KYPROLIS Revenue	75.67M	66.17M	Log In	Log In	Log In	Upgrade
POBEVCY Revenue	48.60M	53.51M	Log In	Log In	Log In	Upgrade
REVLIMID Revenue	-	36.03M	Log In	Log In	Log In	Upgrade
VIDAZA Revenue	-	-	Log In	Log In	Log In	Upgrade
Pamiparib Revenue	-	-	Log In	Log In	Log In	Upgrade
Other Product Revenue	-	60.04M	Log In	Log In	Log In	Upgrade
Total Other Product Revenue	80.96M	96.07M	Log In	Log In	Log In	Upgrade
Total Product Revenue	4.92B	3.78B	Log In	Log In	Log In	Upgrade
Collaboration Revenue	49.03M	30.70M	Log In	Log In	Log In	Upgrade
Revenue (Total)	4.97B	3.81B	Log In	Log In	Log In	Upgrade

Updated Sep 30, 2025. Data Source: Fiscal.ai.